Pirker et al. 1 have published the results of a multinational phase III trial (FLEX; First-Line Erbitux in Lung Cancer) that randomly assigned 1,125 patients with chemotherapy-naive, EGFR ...

LONG BEACH, Calif. -- Both sparsentan (Filspari) and irbesartan were associated with significantly slower estimated glomerular filtration rate (eGFR) decline compared with standard of care in ...